Stallergenes Greer

Last updated
Stallergenes Greer
Company type Private
IndustryPharmaceutical industry
Founded2015;9 years ago (2015)
Headquarters Baar, Switzerland
Key people
Stefan Meister (Chairman), Michele Antonelli (Chief Executive Officer), Giampiero De Luca (Board member)
RevenueIncrease2.svg 277 million (2018) [1]
12,8 M€ (2018)
Number of employees
1045 (2021)

Stallergenes Greer International AG is a global biopharmaceutical company headquartered in Baar, Switzerland, specializing in the diagnosis and treatment of respiratory allergies through immunotherapy. [2]

Contents

Stallergenes Greer International AG is the parent company of GREER Laboratories, Inc. [3] (registered office in the U.S.) and Stallergenes S.A.S. (registered office in France). [4]

With 1035 employees in 2021, [5] Stallergenes Greer operates in 19 countries. [6]

Stallergenes Greer's core manufacturing facilities are located both in Europe (Antony and Amilly in France) and in the USA (Lenoir, North Carolina and San Diego, California). [7]

History

Stallergenes was founded in 1962 by Institut Mérieux [8] [9] [10] [11] In 2015, Stallergenes and Greer Laboratories Inc. merged to form Stallergenes Greer, "a worldwide leader in allergy immunotherapy". [12] [13]

Greer was founded by R.T. Greer, a collecter of source materials (i.e.: roots, herbs, pollens) in 1904. [14]

Stallergenes Greer is a privately held company owned by B-Flexion (ex Waypoint Capital), chaired by Ernesto Bertarelli. [15]

Activity

Stallergenes Greer is specialised in allergy immunotherapy treatments. It includes Name Patient Products (NPP) which are allergen products, prepared in accordance with prescriptions for individual patients. [16]

The product portfolio covers different segments including sublingual products (Staloral®, Oralair®, Actair®), subcutaneous products (Alustal®/Phostal®, Alyostal®/Albey®), allergen extracts available as a bulk extract or NPP, veterinary products, testing supplies, source materials and other supplies like sterile diluents, sterile empty vials.

Board of directors

The board of directors includes: [17] [18]

A pharmaceutical and clinical development programme

Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies. [ citation needed ] [19]

Oralair is the first sublingual immunotherapy tablet resulting from this programme. Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.[ citation needed ] [20] [21]

The second project in this programme is the house dust mite immunotherapy tablet Actair which is marketed in Japan, Australia, and New Zealand, [22] [23] and South Korea under the brand name Actair and in Germany under the brand name Orylmyte. [24]

In 2021, Stallergenes Greer is partnering with Aptar Pharma to develop a novel connected device for allergen immunotherapy treatment delivery. It will contribute to improving adherence, thus optimising treatment outcomes. [25]

Related Research Articles

<span class="mw-page-title-main">Allergy</span> Immune system response to a substance that most people tolerate well

Allergies, also known as allergic diseases, are various conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. Symptoms may include red eyes, an itchy rash, sneezing, coughing, a runny nose, shortness of breath, or swelling. Note that food intolerances and food poisoning are separate conditions.

An allergen is a type of antigen that produces an abnormally vigorous immune response in which the immune system fights off a perceived threat that would otherwise be harmless to the body. Such reactions are called allergies.

<span class="mw-page-title-main">Ragweed</span> Genus of plants

Ragweeds are flowering plants in the genus Ambrosia in the aster family, Asteraceae. They are distributed in the tropical and subtropical regions of the Americas, especially North America, where the origin and center of diversity of the genus are in the southwestern United States and northwestern Mexico. Several species have been introduced to the Old World and some have naturalized and have become invasive species. Ragweed species are expected to continue spreading across Europe in the near future in response to ongoing climate change.

<span class="mw-page-title-main">Allergic rhinitis</span> Nasal inflammation due to allergens in the air

Allergic rhinitis, of which the seasonal type is called hay fever, is a type of inflammation in the nose that occurs when the immune system overreacts to allergens in the air. Signs and symptoms include a runny or stuffy nose, sneezing, red, itchy, and watery eyes, and swelling around the eyes. The fluid from the nose is usually clear. Symptom onset is often within minutes following allergen exposure, and can affect sleep and the ability to work or study. Some people may develop symptoms only during specific times of the year, often as a result of pollen exposure. Many people with allergic rhinitis also have asthma, allergic conjunctivitis, or atopic dermatitis.

<span class="mw-page-title-main">Allergic conjunctivitis</span> Medical condition

Allergic conjunctivitis (AC) is inflammation of the conjunctiva due to allergy. Although allergens differ among patients, the most common cause is hay fever. Symptoms consist of redness, edema (swelling) of the conjunctiva, itching, and increased lacrimation. If this is combined with rhinitis, the condition is termed allergic rhinoconjunctivitis (ARC).

<span class="mw-page-title-main">Allergen immunotherapy</span> Medical treatment for environmental allergies

Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for environmental allergies, such as insect bites, and asthma. Immunotherapy involves exposing people to larger and larger amounts of allergens in an attempt to change the immune system's response.

<span class="mw-page-title-main">Peanut allergy</span> Type of food allergy caused by peanuts

Peanut allergy is a type of food allergy to peanuts. It is different from tree nut allergies, because peanuts are legumes and not true nuts. Physical symptoms of allergic reaction can include itchiness, hives, swelling, eczema, sneezing, asthma attack, abdominal pain, drop in blood pressure, diarrhea, and cardiac arrest. Anaphylaxis may occur. Those with a history of asthma are more likely to be severely affected.

<span class="mw-page-title-main">Milk allergy</span> Type of food allergy caused by milk

Milk allergy is an adverse immune reaction to one or more proteins in cow's milk. Symptoms may take hours to days to manifest, with symptoms including atopic dermatitis, inflammation of the esophagus, enteropathy involving the small intestine and proctocolitis involving the rectum and colon. However, rapid anaphylaxis is possible, a potentially life-threatening condition that requires treatment with epinephrine, among other measures.

ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy (AIT) products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products with 67% of its revenue coming from sales in Europe.

<span class="mw-page-title-main">Tree nut allergy</span> Medical condition

A tree nut allergy is a hypersensitivity to dietary substances from tree nuts and edible tree seeds causing an overreaction of the immune system which may lead to severe physical symptoms. Tree nuts include almonds, Brazil nuts, cashews, chestnuts, filberts/hazelnuts, macadamia nuts, pecans, pistachios, shea nuts and walnuts.

<span class="mw-page-title-main">Mattress protector</span> Bedding product

A mattress protector is an item of removable bedding that sits on top of, or encases, a mattress to protect it. Some mattress protectors also provide protection to the person sleeping on the mattress from allergens and irritants such as dust mites, bed bugs, mold, and dead skin.

Dogs are susceptible to allergies much like their human companions. Most allergies occur in dogs over 6 months old. A dog that is repeatedly exposed to a particular allergen becomes sensitized to it, and the immune system overreacts to a subsequent exposure, most commonly manifesting in the form of skin irritation. Some of the signs are redness, itching, hair loss, and recurring skin infections from the irritation. Skin irritation may be generalized or localized. The dog may be more prone to scratching and licking at the irritated site, further exacerbating the problem.

<span class="mw-page-title-main">Asthma and Allergy Friendly</span>

Asthma & Allergy Friendly is a registered certification mark operated by Allergy Standards Limited in association with not-for-profit asthma and/or allergy organizations. They specialise in labelling products which have been put through and have passed standardised testing. The Asthma & Allergy Friendly Certification Program was created to scientifically test and identify consumer products that are more suitable for people with asthma and allergies.

GA²LEN, or Global Allergy and Asthma European Network, is a consortium of leading European research centres specialized in allergic diseases, which include asthma. Funded by the European Union under the 6th Framework Programme, GA²LEN addresses the growing public health concern of allergic diseases.

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

<span class="mw-page-title-main">Peptidase 1 (mite)</span> Class of enzymes found in mites

Peptidase 1 (mite) (EC 3.4.22.65), also known as endopeptidase 1 (mite), is an enzyme found in various species of mites. This enzyme exhibits cysteine protease activity with broad endopeptidase specificity.

<span class="mw-page-title-main">HAL Allergy Group</span>

HAL Allergy Group is a pharmaceutical company that develops, produces and sells products for allergy diagnostic and allergen immunotherapy (AIT). The research facilities and headquarters are located at the Leiden Bio Science Park, Netherlands.

<span class="mw-page-title-main">Dust mite allergy</span> Medical condition

Dust mite allergy, also known as house dust allergy, is a sensitization and allergic reaction to the droppings of house dust mites. The allergy is common and can trigger allergic reactions such as asthma, eczema or itching. The mite's gut contains potent digestive enzymes that persist in their feces and are major inducers of allergic reactions such as wheezing. The mite's exoskeleton can also contribute to allergic reactions. Unlike scabies mites or skin follicle mites, house dust mites do not burrow under the skin and are not parasitic.

<span class="mw-page-title-main">Shellfish allergy</span> Type of food allergy caused by shellfish

Shellfish allergy is among the most common food allergies. "Shellfish" is a colloquial and fisheries term for aquatic invertebrates used as food, including various species of molluscs such as clams, mussels, oysters and scallops, crustaceans such as shrimp, lobsters and crabs, and cephalopods such as squid and octopus. Shellfish allergy is an immune hypersensitivity to proteins found in shellfish. Symptoms can be either rapid or gradual in onset. The latter can take hours to days to appear. The former may include anaphylaxis, a potentially life-threatening condition which requires treatment with epinephrine. Other presentations may include atopic dermatitis or inflammation of the esophagus. Shellfish is one of the eight common food allergens, responsible for 90% of allergic reactions to foods: cow's milk, eggs, wheat, shellfish, peanuts, tree nuts, fish, and soy beans.

Curex is an American telehealth company specializing in immunology, specifically the diagnosis and treatment of allergies, including the prescription and delivery of allergy immunotherapy. The company was founded by Gene Kakaulin and Charles Jacoby in 2020 and is headquartered in New York City. Curex offers a virtual platform that connects patients with doctors for allergy care.

References

  1. "Annual report" (PDF). stallergenesgreer.com. 2018.
  2. "STALLERGENES GREER LTD". Companies House.
  3. "STALLERGENES GREER LTD". Companies House.
  4. "STALLERGENES SAS". infogreffe.fr.
  5. "Key facts and figures". stallergenesgreer.com.
  6. "Global Network | stallergenesgreer.com". www.stallergenesgreer.com. Retrieved 2020-05-21.
  7. "Annual Report 2018" (PDF). 2018.
  8. "Stallergenes Greer". Ville d'Antony. Archived from the original on 2019-10-25.
  9. "Le leader de la lutte contre les allergies fête ses 50 ans". Le Parisien. 12 December 2012.
  10. "Grand Oralair". Les Echos. 3 April 2014.
  11. "COR-Stallergènes envisage des acquisitions en 2013". Challenges. 21 December 2012.
  12. "Labos: fusion de Stallergenes et Greer bouclée". Le Figaro. 8 September 2015.
  13. "Stallergenes and Greer to create the World Leader in Allergy Immunotherapy - Labiotech.eu". 30 June 2015.
  14. "History - stallergenesgreer.com". stallergenesgreer.com.
  15. "Stallergenes Greer : Waypoint détient la totalité du capital; sortie du marché ce 17 mai". 17 May 2019.
  16. "Collège de la Haute Autorité de Santé - Projet de recommandation" (PDF). Haute autorité de santé. 13 December 2017.
  17. "BOARD OF DIRECTORS" . Retrieved 2019-10-25.
  18. "Stallergenes : résultats semestriels en hausse, changement de direction". capital.fr. 30 August 2018.
  19. "Stallergènes Anti-allergènes sur mesure". 30 June 2005.
  20. "Aux États-Unis, Stallergenes impose ses anti-allergiques". 10 April 2014.
  21. "Le spécialiste des allergies à l'assaut des Etats-Unis". 8 April 2014.
  22. "Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer's Sublingual House Dust Mite Allergen Immunotherapy Tablet". financialpost. Retrieved 2021-09-14.
  23. "Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint". Business Wire. 20 November 2018.
  24. "Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer's Sublingual House Dust Mite Allergen Immunotherapy Tablet". businesswire.com. 31 May 2021.
  25. "Stallergenes Greer choisit Aptar pour son dispositif médical connecté". usinenouvelle.com. 21 November 2021.